Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

Understanding the real-world effectiveness and safety of insulin biosimilars

EF 2025-26

Résumé
Biologics are newer drugs that are made by living organisms. They have greatly improved outcomes and changed lives for many patients living with medical conditions that were previously not well-treated, such as insulin for diabetes, but are associated with high cost. The patents for many innovator biologics have expired, allowing biosimilars to enter the market. For a biosimilar to be approved, clinical trials must demonstrate that it has similar efficacy and safety as the innovator biologic. Biosimilars cost much less than innovator biologics. They can improve accessibility for patients and sustainability for public payers. In 2023, the Ontario government began requiring patients on various insulin products to switch to biosimilars to maintain public drug coverage. However, clinicians and patients are reluctant to use biosimilars, especially for patients who have responded well to innovator products. To support this switch, the Ontario government reimbursed community pharmacists for educating patients on the efficacy and safety of the biosimilars. Although biosimilars are supported by clinical trials, real-world evidence in Canada is limited and largely focused on inflammatory conditions rather than diabetes. To inform pharmacists on how to best support insulin users, the proposed research will: (1) review the real-world effectiveness and safety of insulin biosimilars, (2) evaluate the impact of Ontario's biosimilar switch policy on patients' clinical outcomes, and (3) compare the real-world effectiveness and safety of insulin biosimilars versus innovator products in Ontario. The findings can guide clinicians and support policy decisions on the disease management of hundreds of thousands of Canadians and patients worldwide.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559738
Name
Ho Martin K
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
DT2 (Health services and population health research) CGRS Doctoral
Projecttitle
Understanding the real-world effectiveness and safety of insulin biosimilars
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Biologic Drugs; Biosimilars; Comparative Drug Effectiveness And Safety; Diabetes Mellitus; Health Policy; Insulin; Pharmacoepidemiology
Abstract
Biologics are newer drugs that are made by living organisms. They have greatly improved outcomes and changed lives for many patients living with medical conditions that were previously not well-treated, such as insulin for diabetes, but are associated with high cost. The patents for many innovator biologics have expired, allowing biosimilars to enter the market. For a biosimilar to be approved, clinical trials must demonstrate that it has similar efficacy and safety as the innovator biologic. Biosimilars cost much less than innovator biologics. They can improve accessibility for patients and sustainability for public payers. In 2023, the Ontario government began requiring patients on various insulin products to switch to biosimilars to maintain public drug coverage. However, clinicians and patients are reluctant to use biosimilars, especially for patients who have responded well to innovator products. To support this switch, the Ontario government reimbursed community pharmacists for educating patients on the efficacy and safety of the biosimilars. Although biosimilars are supported by clinical trials, real-world evidence in Canada is limited and largely focused on inflammatory conditions rather than diabetes. To inform pharmacists on how to best support insulin users, the proposed research will: (1) review the real-world effectiveness and safety of insulin biosimilars, (2) evaluate the impact of Ontario's biosimilar switch policy on patients' clinical outcomes, and (3) compare the real-world effectiveness and safety of insulin biosimilars versus innovator products in Ontario. The findings can guide clinicians and support policy decisions on the disease management of hundreds of thousands of Canadians and patients worldwide.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ho, Martin K
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~